Table 3 Overall efficacy and response to treatment with nal-IRI + 5-FU/LV
N = 56 (%) | |
|---|---|
PFS (median, mo) | 2.9 |
OS (median, mo) | 5.3 |
Response rate | |
Partial response | 3 (5) |
Stable disease | 23 (41) |
Progressive disease | 23 (41) |
Not evaluabe | 7 (13) |
CA 19–9 response (maximal response/baseline) | |
> 1 | 19 (34) |
0.5 to 1 | 15 (27) |
< 0.5 | 10 (18) |
not evaluable | 10 (18) |
not measurable | 2 (4) |
Advanced disease, OS (median, mo) | |
All | 24.2 |
Sequence 1 | 25.5 |
Sequence 2 | 23.0 |
nab-P + Gem → Gem/Cap → nal-IRI + 5-FU/LV | 28.6 |
other | 23.0 |